In CRC samples, higher levels of myeloid cell CCR2 were seen in tumors harboring mismatch repair deficiency/microsatellite instability–high than in microsatellite stable carcinomas, and this difference was predominant when measuring CCR2 in CD68+ TAMs (Fig. 6G). The gene discussed is CD68; the disease is carcinoma.